Progress with investigational drugs for the treatment of pulmonary and inflammatory diseases

This publication has 13 references indexed in Scilit:

• Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Differential interactions of prostaglandin endoperoxide synthases with nonsteroidal anti-inflammatory drugs
  Expert Opinion on Investigational Drugs, 1994
• The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin
  American Review of Respiratory Disease, 1993
• Substituted 3-(phenylmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes
  Journal of Medicinal Chemistry, 1993
• Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 {(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds
  Biochemical Pharmacology, 1993
• In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis
  Inflammation Research, 1993
• Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors
  Journal of Medicinal Chemistry, 1992
• Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor
  Canadian Journal of Physiology and Pharmacology, 1992
• Mitogen‐inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs
  Drug Development Research, 1992
• Urinary Leukotriene E₄Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects
  American Review of Respiratory Disease, 1991
• Reduced Allergen-Induced Nasal Congestion and Leukotriene Synthesis with an Orally Active 5-Lipoxygenase Inhibitor
  New England Journal of Medicine, 1990